<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767091</url>
  </required_header>
  <id_info>
    <org_study_id>2008-002578-36</org_study_id>
    <secondary_id>2008/0817</secondary_id>
    <nct_id>NCT00767091</nct_id>
  </id_info>
  <brief_title>Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia</brief_title>
  <acronym>CHoPA-I</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentric Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apathy usually refers to a set of behavioural, emotional and cognitive features as a reduced&#xD;
      interest and participation in main activities of daily life, a lack of initiative, a trend&#xD;
      toward an early withdrawal from started activities, an indifference and a flattening of&#xD;
      affect. We have validated a new specific scale (Lille Apathy Rating Scale, LARS) in order to&#xD;
      detect and quantify apathy in Parkinson's disease (PD). Apathy was shown to be frequent in PD&#xD;
      with a prevalence of 32%. It has suggested that the medial frontal and limbic cholinergic&#xD;
      deficits may underlie apathy in neurodegenerative disorders like Alzheimer's disease (AD).&#xD;
      Such a hypothesis is supported by recent evidence indicating the beneficial effects of&#xD;
      cholinesterase inhibitors on neuropsychiatric symptoms, mainly apathy, in AD patients. As the&#xD;
      efficacy of rivastigmine on cognition has also been shown in PD, we aimed to assess with a&#xD;
      randomized, double-blind, placebo-controlled, parallel-group, multicenter trial, the efficacy&#xD;
      and acceptability of a 6 months treatment with rivastigmine on apathy in 60 patients with PD&#xD;
      without dementia. The primary end point will be the LARS score and the secondary end points&#xD;
      will be the cognitive, behavioural and motor symptoms of PD. Two add-on studies will be&#xD;
      proposed: first the measure of choline and glutamate peaks on Magnetic Resonance Spectrometry&#xD;
      focused on the structures implicated in apathy in order to give insights in the&#xD;
      physiopathological mechanisms of the treatment. Secondly, the recording of the REM sleep&#xD;
      behavior disorders in relation with the cholinergic part of the pedunculopontine nucleus.&#xD;
      Regarding that apathy could be one of the first steps toward PD dementia, treating very early&#xD;
      could have substantial implications on the patients and their caregiver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall study duration: 2 years. Planned inclusion period: 12 months. Study duration for&#xD;
      individual patients: 7 months (2 weeks between screening and randomization, 6 months of&#xD;
      double-blind treatment and then a 2-week wash-out period).&#xD;
&#xD;
      Primary objective (V1 and V6):&#xD;
&#xD;
      To assess efficacy of anticholinesterasic treatment (trans-dermal patch of rivastigmine ,&#xD;
      Exelon®) on parkinsonian apathy assessed by the Lille Apathy Rating Scale in patients with&#xD;
      advanced Parkinson's disease without dementia or depression&#xD;
&#xD;
      Additional Efficacy Endpoints (V1 and V6):&#xD;
&#xD;
        -  the NeuroPsychiatric Inventory, the apathy/retardation subscore of the MADRS&#xD;
           (tri-dimensional analysis, the Activity of Daily Living scale, the simple and complex&#xD;
           reaction times (selective attention), the quality of life (PDQ-39), the &quot;Zarit&quot; scale&#xD;
           and the Clinical Global Impression of Change, Independence Scale, Mattis score, MMSE&#xD;
&#xD;
        -  Gait: time and number of steps and freezing at the Stand Walk Sit test, the Tinetti&#xD;
           scale, the UPDRS I, II, III et IV, the self questionnaire of Giladi&#xD;
&#xD;
        -  Sleep quality: during two successive polysomnography recordings (sleep pattern, measures&#xD;
           of the rapid eye movement (REM) sleep time, daytime sleepiness (PDSS and Epworth), and&#xD;
           Sleep Latency Test&#xD;
&#xD;
        -  Magnetic Resonance Spectroscopy on the measures of the choline/creatine and&#xD;
           glutamate/creatine peaks (medial frontal cortex, limbic cortex, caudate nucleus,&#xD;
           putamen, pedunculopontine nucleus) on 3 Tesla MRI&#xD;
&#xD;
      Safety and Tolerability Endpoints (V1, V3 and V6):&#xD;
&#xD;
      Safety and tolerability will be evaluated with reference to the following:&#xD;
&#xD;
        1. Tolerability :&#xD;
&#xD;
           Number of subjects (%) who discontinue the study, Number of subjects (%) who discontinue&#xD;
           the study due to AEs.&#xD;
&#xD;
        2. Safety Measures :&#xD;
&#xD;
      AE incidence, Safety laboratory values, Vital signs, Blood pressure monitoring, ECG, Physical&#xD;
      and neurological examination.&#xD;
&#xD;
      Study Design&#xD;
&#xD;
      Multicentric pilot study: 36-week double blind, placebo-controlled phase. After being found&#xD;
      eligible to participate in the study, subjects will be allocated in a 1:1 ratio into one of&#xD;
      the following two treatment groups based on a randomization scheme with blocks stratified:&#xD;
&#xD;
        1. one patch of 4.6 mg/day during 1 month, then one patch of 9.5 mg/day during 5 months&#xD;
&#xD;
        2. one patch of placebo during 6 months&#xD;
&#xD;
      Schedule: 7 visits&#xD;
&#xD;
        -  Four consultations: screening (V0), randomisation (V1, 15 days after V0), (V3) visit&#xD;
           after 3 months and termination (V7, 6 months after randomisation)&#xD;
&#xD;
        -  Two phone calls (V2, V4)&#xD;
&#xD;
      Patients :&#xD;
&#xD;
      60 subjects with Parkinson's disease duration of more than 5 years, without dementia (Mattis&#xD;
      Dementia Rating Scale ≥ 130, MMSE ≥ 27 and DSM IV), without major depression (MADRS &lt; 18) who&#xD;
      have developed apathy (defined by a score of - 16 or more at the LARS) despite an optimal&#xD;
      dopaminergic treatment No additional therapy will be permitted during the study.&#xD;
&#xD;
      Investigational Medicinal Product (IMP) &amp; Dosage:&#xD;
&#xD;
      Rivastigmine, or matching placebo, administered by transdermal patch a day in the morning:&#xD;
&#xD;
      4.6 mg a day during one month, 9.5 mg a day during five months&#xD;
&#xD;
      Centres :&#xD;
&#xD;
      Lille :&#xD;
&#xD;
        -  Department of Neurology, University Hospital, Lille : Pr L. Defebvre, Pr K. Dujardin, Dr&#xD;
           D. Devos, Pr Destee, Mme Delliaux. Dr A Kreisler, Dr C Simonin, Dr C. Moreau&#xD;
&#xD;
        -  Department of Pharmacology, Faculté de Médecine, Lille II : R. Bordet&#xD;
&#xD;
        -  Department of Clinical Neurophysiology, sleep laboratory : Pr P. Derambure, Dr C. Monaca&#xD;
&#xD;
        -  Department of Neuroradiology : Pr J. Pruvo Dr C. Delmaire Dr P. Jissendi, Dr G. Soto&#xD;
           Ares, Pr X. Leclerc&#xD;
&#xD;
        -  Department of Statistics, CERIM, Faculté de Médecine Lille II : Dr P. Devos, Dr A.&#xD;
           Duamel&#xD;
&#xD;
        -  Lille III University : Dr P. Sockeel Méthodologiste&#xD;
&#xD;
      Amiens :&#xD;
&#xD;
      - Department of Neurology, University Hospital, Amiens : Pr P. Krystkowiak, Pr O. Godefroy,&#xD;
      Dr Gérard, Dr Dupuy, Pr Deramon, Pr JM Macron, Dr Rose&#xD;
&#xD;
      Rouen :&#xD;
&#xD;
      - Department of Neurology, University Hospital, Rouen, . Dr D. Maltête, Pr. D. Hannequin, Dr.&#xD;
      O. Martinaud, Dr E. Gérardin, Pr. B. Mihout, Mmes C. Aubier-Girard, S Bioux, E. Bliaux, D.&#xD;
      Pouliquen&#xD;
&#xD;
      Caen :&#xD;
&#xD;
      - Department of Neurology, University Hospital,Caen, : Pr G. Defer, Pr F. Viader, Dr Guillamo&#xD;
      Dr Marié, Dr Carluer, Mme Lebrun&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure on the scale : Lille Apathy Rating Scale (LARS)</measure>
    <time_frame>6 months</time_frame>
    <description>measure of the reduction of apathy with this qualitative scale from -36 +36 with the cut off -16</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive, motor and behaviour assessment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Apathy</condition>
  <condition>no Dementia</condition>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A: transdermal rivastigmine at 4.6 mg per day during one month then 9.5 mg per day during 5 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>transdermal patch of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivastigmine</intervention_name>
    <description>transdermal patch of rivastigmine of 9.5 mg/day</description>
    <arm_group_label>Active treatment</arm_group_label>
    <other_name>cholinesterase inhibitors (Exelon)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>transdermal patch of placebo</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>transdermal patch without active substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Parkinson's disease: Gibb and Gelb criteria&#xD;
&#xD;
          -  Apathy defined by a score of - 16 or more on the LARS scale (Sockeel et al., 2006)and&#xD;
             criteria of Marin (1991)&#xD;
&#xD;
          -  No dementia according to DSM IV with MMSE Score≥ 27 and Mattis score≥ 130&#xD;
&#xD;
          -  Under stable dopaminergic treatment for 3 months&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Depression according to DSM-IV criteria and a score &lt; 18 on the MADRS&#xD;
&#xD;
          -  Subthalamic stimulation of less than one year&#xD;
&#xD;
          -  Subthalamic stimulation without stable parameters for 3 months&#xD;
&#xD;
          -  Subject older than 80 years&#xD;
&#xD;
          -  Severe rest tremor with a subscore &gt; or= 3 on the UPDRS part&#xD;
&#xD;
          -  Parkinson related Psychosis in progress&#xD;
&#xD;
          -  Hypersensibility to cholinesterase inhibitors or carbamates&#xD;
&#xD;
          -  Myocardial infarction, other cardiac affections&#xD;
&#xD;
          -  Severe hepatic insufficiency&#xD;
&#xD;
          -  Sever medical illness&#xD;
&#xD;
          -  Skin diseases interfering with transdermal patch&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Incapacity to give the consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Devos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Devos</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>September 1, 2008</study_first_submitted>
  <study_first_submitted_qc>October 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2008</study_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Apathy</keyword>
  <keyword>Rivastigmine</keyword>
  <keyword>transdermal patch</keyword>
  <keyword>anticholinesterasic</keyword>
  <keyword>acetylcholine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivastigmine</mesh_term>
    <mesh_term>Cholinesterase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

